TRCT
NRXP icon

Tower Research Capital (TRC)’s NRX Pharmaceuticals NRXP Stock Holding History

Tower Research Capital (TRC)’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Buy
3,884
+3,803
+4,695% +$12.6K ﹤0.01% 3741
2026
Q1 		$173 Buy
81
+80
+8,000% +$161 ﹤0.01% 4970
2025
Q4 		$3 Sell
1
-323
-100% -$867 ﹤0.01% 5112
2025
Q3 		$1.07K Sell
324
-832
-72% -$2.38K ﹤0.01% 4884
2025
Q2 		$3.77K Buy
+1,156
New +$2.9K ﹤0.01% 4437
2024
Q4 		– Sell
-2,544
Closed -$4.3K – 5903
2024
Q3 		$4.3K Sell
2,544
-783
-24% -$1.58K ﹤0.01% 4598
2024
Q2 		$8.12K Buy
3,327
+1,184
+55% +$4.21K ﹤0.01% 4394
2024
Q1 		$10.1K Buy
2,143
+173
+9% +$797 ﹤0.01% 3744
2023
Q4 		$9.06K Buy
1,970
+1,052
+115% +$3.48K ﹤0.01% 4441
2023
Q3 		$2.39K Sell
918
-1,876
-67% -$6.24K ﹤0.01% 5164
2023
Q2 		$13.5K Buy
2,794
+1,310
+88% +$7.88K ﹤0.01% 3759
2023
Q1 		$10K Buy
1,484
+874
+143% +$8.86K ﹤0.01% 4381
2022
Q4 		$7K Sell
610
-684
-53% -$6.89K ﹤0.01% 4592
2022
Q3 		$10K Buy
1,294
+889
+220% +$5.99K ﹤0.01% 4551
2022
Q2 		$2K Sell
405
-108
-21% -$1.42K ﹤0.01% 5573
2022
Q1 		$13K Buy
513
+491
+2,232% +$16K ﹤0.01% 3989
2021
Q4 		$1K Sell
22
-81
-79% -$5.84K ﹤0.01% 5867
2021
Q3 		$10K Buy
103
+90
+692% +$11.7K ﹤0.01% 4329
2021
Q2 		$1K Buy
13
+3
+30% +$792 ﹤0.01% 5225
2021
Q1 		$4K Buy
+10
New +$3.62K ﹤0.01% 4798

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tower Research Capital (TRC)'s NRXP Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its NRX Pharmaceuticals (NRXP) stake by 4,695% in Q2 2026, buying an estimated $12.6K and bringing the position to 3,884 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3741.

Tower Research Capital (TRC) first reported a position in NRXP in Q1 2021 and has held it in 20 quarters since. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Tower Research Capital (TRC) held 3,884 shares of NRX Pharmaceuticals worth $15.9K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,803 NRX Pharmaceuticals shares in Q2 2026, an estimated $12.6K.
  • NRX Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3741 holding.
  • Tower Research Capital (TRC) first reported a position in NRX Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • 46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.